Revcovi is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

The global Revcovi market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Revcovi volume and value at global level, regional level and company level. From a global perspective, this report represents overall Revcovi market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Revcovi in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Revcovi manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Leadiant Biosciences
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Pre-filled
Vial

Segment by Application
Hospital
Pharmacy